Randall James Osborn, CNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 719 Detroit Ave, Danville, AR 72833 Phone: 479-495-2241 Fax: 479-495-6299 |
Ms. Sherry Lynn Loyd, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 719 Detroit Ave, Danville, AR 72833 Phone: 479-495-2241 Fax: 479-495-6309 |
Pamela Lou Dollar, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 719 Detroit Ave, Danville, AR 72833 Phone: 479-495-2241 Fax: 479-495-6299 |
Shannon Golden, APN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 719 Detroit Ave, Danville, AR 72833 Phone: 479-495-2241 |
Kathryn E Pledger, CNP Nurse Practitioner - Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 719 Detroit Ave, Danville, AR 72833 Phone: 479-495-6270 Fax: 479-495-6299 |
News Archive
Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced select year-end financial and operational results for 2014, which include record-setting revenue and continued case volume growth for its panomic, comprehensive tumor profiling service, Caris Molecular Intelligence.
Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved survival rates among diabetes patients.
Tucked into the lower, rear portion of the brain, the cerebellum plays key roles in motor learning, motor memory and sensory perception. It's also where the majority of metastatic childhood brain tumors are located. Yet scientists still know very little about its early growth.
Almost 70 percent of uninsured Texans said the high cost of health insurance is the reason they remain uninsured, according to a new report released today by Rice University's Baker Institute for Public Policy and the Episcopal Health Foundation.
Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.
› Verified 5 days ago